AZD6140. Antiplatelet therapy P2Y12 (P2T) receptor antagonist

Drugs of the Future

Volumn 32, Issue 10, 2007, Pages 845-853

  Owen, R T ^a   Serradell, N ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRONCHOSPASM; CHEMICAL REACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYCLOPROPANATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DYSPNEA; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; ST SEGMENT ELEVATION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

EID: 36749058370     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.10.1133832     Document Type: Article

References (34)

1. Guile, S., Hardern, D., Willis, P., Springthorpe, B., Ingall, A. (AstraZeneca AB; AstraZeneca plc). Novel triazolo(4,5-d)pyrimidine compounds. EP 1135391, JP 2002531567, JP 2007084551, US 2003144305, US 2006025590, US 6525060, WO 0034283.
2. Bohlin, M., Lassen, B., Cosgrove, S. (AstraZeneca AB). New crystalline and amorphous form of triazolo(4,5-d)pyrimidine compound. CA 2408596, EP 1289992, EP 1493745, JP 2003535092, US 2003181469, US 2007173518, WO 0192262.
3. Larsson, U., Magnusson, M., Musil, T., Palmgren, A. (AstraZeneca AB). Triazolo pyrimidine compounds. CA 2408914, EP 1299390, JP 2003535093, US 2003148888, US 2006041132, US 2007049755, US 7067663, WO 0192263.
4. Jacobson, A.K. Platelet ADP receptor antagonists: Ticlopidine and clopidogrel. Best Pract Res Clin Haematol 2004, 17(1): 55-64.
5. Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G., Fox, K.K. and the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345(7): 494-502.
6. Sabatine, M.S., Cannon, C.P., Gibson, C.M. et al. for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352(12): 1179-89.
7. Patrono, C., Coller, B., FitzGerald, G.A., Hirsh, J., Roth, G. Platelet-active drugs: The relationships among dose, effectiveness and side-effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3, Suppl.): 234S-64S.
8. Santa-Cruz, R.A., Steinhubl, S.R. Clopidogrel: How good is it and how does it work? Curr Cardiol Rep 2004, 6(4): 264-8.
9. Wiviott, S.D., Antman, E.M. Clopidogrel resistance: A new chapter in a fast-moving story. Circulation 2004, 109(25): 3064-7.
10. Jaremo, P., Lindahl, T.L., Fransson, S.G., Richter, A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Int Med 2002, 252: 233-8.
11. Gurbel, P.A., Bilden, K.P., Hiatt, B.L., O'Connor, C.M. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107(23): 2908-13.
12. Gurbel, P.A., Tantry, U.S. Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006, 3(7): 387-95.
13. Matetzky, S., Shenkman, B., Guetta, V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109(25): 3171-5.
14. Conley, P.B., DeLaney, S.M. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr Opin Hematol 2003, 10(5): 333-8.
15. Husted, S., Emanuelsson, H., Heptinstall, S., Sandset, P.M., Wickens, M., Peters, G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006, 27(9): 1038-47.
16. Peters, G., Robbie, G. Single dose pharmacokinetics and pharmacodynamics of AZD6140, an oral reversible ADP receptor antagonist. Haematologica 2004, 89(Suppl. 7): 14-5.
17. van Giezen, J.J.J., Humphries, R.G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005, 31(2): 195-204.
18. Schäfer, A., Schöpp, C., Neumüller, J. et al. Rapid inhibition of platelet reactivity with AZD6140 in rats with streptozotocin- induced diabetes. 8th Annu Conf Arterioscler Thromb Vasc Biol (April 19-21, Chicago) 2007, Abst P90.
19. Patil, S.B.G., Norman, K.E., Robins, S.J. et al. Inhibition of thrombosis by AZD6140 via selective blockade of the P2Y12 receptor in a murine laser-injury model. 21st Int Soc Thromb Haemost Congr (July 6-12, Geneva) 2007, Abst P-W-632.
20. Björkman, J.A., van Giezen, J.J.J., Zachrisson, H. Reduced bleeding time prolongation for the reversible P2Y12 antagonist AZD6140 compared with the thienopyridine clopidogrel in both a rat and a dog model of combined thrombosis and haemostasis. 21st Int Soc Thromb Haemost Congr (July 6-12, Geneva) 2007, Abst P-M-279.
21. Wihlborg, A.K., Wang, L., Braun, O.O., Eyjolfsson, A., Gustafsson, R., Gudbjartsson, J., Erlinge, D. The ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004, 24(10): 1810-5.
22. Svensson, H., Erlinge, D. The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in mouse aorta in addition to established inhibition effects on platelet aggregation. 8th Annu Conf Arterioscler Thromb Vasc Biol (April 19-21, Chicago) 2007, Abst P564.
23. Peters, G., Butler, K., Winter, H.R., Mitchell, P.D. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of the reversible oral ADP receptor antagonist AZD6140. Eur Heart J [World Congr Cardiol (Sept 2-6, Barcelona) 2006] 2006, 27(Abstract Suppl.): Abst P4556.
24. Husted, S., Emanuelsson, H., Heptinstall, S., Clark, S., Peters, G. Greater and less variable inhibition of platelet aggregation with AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with atherosclerosis. Eur Heart J [ESC Congr (Sept 3-7, Stockholm) 2006] 2006, 27: Abst 3764.
25. Cannon, C.P., Husted, S., Storey, R.F. et al. The DISPERSE2 trial: Safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome. Circulation [78th Am Heart Assoc Sci Sess (Nov 13-16, Dallas) 2005] 2005, 112(17, Suppl. 2): Abst 2906.
26. Emanuelsson, H., Mahaffey, K.W., Harrington, R.A. et al. Can greater inhibition of platelet aggregation be tolerated? Evaluation of the bleeding risk of AZD6140 compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS). J Am Coll Cardiol [55th Annu Sci Sess Am Coll Cardiol (ACC) (March 11-14, Anaheim) 2006] 2006, 47(4, Suppl. 1): Abst 995-223.
27. Cannon, C.P., Harrington, R.A., Mahaffey, K.W. et al. Clinical outcomes with AZD6140, an oral reversible ADP receptor antagonist with clopidogrel in patients with acute coronary syndromes (ACS). J Am Coll Cardiol [55th Annu Sci Sess Am Coll Cardiol (ACC) (March 11-14, Anaheim) 2006] 2006, 47(4, Suppl. 1): Abst 974-242.
28. Husted, S., Storey, R.F., Harrington, R.A. et al. The effects of AZD6140, the first reversible ADP receptor antagonist compared with clopidogrel on biochemical markers in patients with acute coronary syndromes. J Am Coll Cardiol [55th Annu Sci Sess Am Coll Cardiol (ACC) (March 11-14, Anaheim) 2006] 2006, 47(4, Suppl. 1): Abst 974-245.
29. Storey, R.F., Husted, S., Harrington, R.A. et al. AZD6140 yields greater inhibition of platelet aggregation with clopidogrel in patients with acute coronary syndromes without previous clopidogrel treatment. J Am Coll Cardiol [55th Annu Sci Sess Am Coll Cardiol (ACC) (March 11-14, Anaheim) 2006] 2006, 47(4, Suppl. 1): Abst 821-3.
30. Storey, R.F., Husted, S., Harrington, R.A. et al. AZD6140 yields additional suppression of platelet aggregation in patients with acute coronary syndromes previously treated with clopidogrel. J Am Coll Cardiol [55th Annu Sci Sess Am Coll Cardiol (ACC) (March 11-14, Anaheim) 2006] 2006, 47(4, Suppl. 1): Abst 821-4.
31. Serebruany, V.L., Stebbing, J., Atar, D. Dyspnoea after antiplatelet agents: The AZD6140 controversy. Int J Clin Pract 2007, 61(3): 529-33.
32. Husted, S., van Giezen, J.J.J. Dyspnoea and antiplatelet agents: Revisited. Int J Clin Pract 2007, 61(9): 1590.
33. Tantry, U.S., Bliden, K.P., Gurbel, P.A. AZD6140. Expert Opin Investig Drugs 2007, 16(2): 225-9.
34. A comparison of AZD6140 and clopidogrel in patients with acute coronary syndrome (NCT00391872). ClinicalTrials.gov Web site http://clinicaltrials.gov/ct/show/NCT00391872, September 3, 2007.